CClinicalTrials.gg
CompletedNCT07349459Updated Oct 6, 2026

Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin

An interventional study of Group 1 (Doxorubicin group) and Group 2: Vitamin D group in Melatonin, Breast Cancer Patients Diagnosed and Vitamin D Concentration, sponsored by Tanta University. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Tanta University · Not applicable, Interventional, and Prevention

Updated Oct 6, 2026Now CompletedEnrollment updatedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.

Read the detailed description

Doxorubicin is one of the most potent chemotherapeutic agents and is widely used for the treatment of various cancers and hematological malignancies . Although Doxorubicin has a potential beneficial effect in cancer treatment, its dose-dependent cardio toxicity is considered a major challenge.

Doxorubicin is known to generate free radicals either by redox cycling between a semiquinone form and a quinone form or by forming a Doxorubicin-Fe3+ complex . In both pathways, molecular oxygen is reduced to superoxide ion , which is converted to other forms of reactive oxygen species such as hydrogen peroxide and hydroxyl radical . These free radicals could then cause membrane and macromolecule damage, both of which lead to injury to the heart, an organ that has a relatively low level of antioxidant enzymes such as superoxide dismutase and catalase .

Furthermore, it was revealed that Doxorubicin may enhance the death of cardiomyocytes by affecting the tumor necrosis factor signaling pathway via increasing the expression and levels of inflammatory genes interleukin and interleukin -6 .

To alleviate DOX-induced toxicity, researchers have tested a number of strategies, including the administration of antioxidants and/or antiapoptotic agents, in both in vitro and in vivo models of Doxorubicin induced cytotoxicity, but most of these trials have failed to translate into clinical benefits . As a result, there are no effective approaches for alleviating Doxorubicin induced cytotoxicity despite intensive research over recent decades .

Melatonin is a natural hormone that is primarily secreted by the pineal gland and functions as a major regulator of circadian rhythms in humans . Melatonin also plays a variety of biological roles as a modulator of mood, sexual behavior and sleep; low levels or a deficiency of melatonin are also associated with Parkinson's disease, Alzheimer's disease, epilepsy, ischemic injury, diabetes, and even cancer .

Melatonin has emerged as a promising adjuvant that protects against doxorubicin-induced cytotoxicity, as highlighted by various studies and clinical trials that have demonstrated cardioprotective effects against several chemotherapeutic agents . Moreover, melatonin exhibits low toxicity and easily enters cells owing to its good solubility in both aqueous and organic phases and its highly lipophilic properties . Vitamin D plays an important role in the regulation of body function including the cardiovascular system .

Vitamin D deficiency results in the decrease of active calcitriol leading to inhibition of proliferation of cardiomyocytes and vascular smooth muscles .

This study aims to assess the cardioprotective effect of melatonin and vitamin D in breast cancer patients who receive doxorubicin.

02

Conditions studied

  • Melatonin
  • Breast Cancer Patients Diagnosed
  • Vitamin D Concentration
  • Doxorubicin

Keywords

  • Vitamin D
  • Doxorubicin
  • Cardioprotective Effect
  • Melatonin
  • Breast Cancer Patients
03

In context

Lead sponsor

Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Age from 18 to 65 years old.
  • Gender: female.
  • Positive breast cancer women who are scheduled to receive Doxorubicin.
  • Have a good performance status according to the eastern cooperative oncology group with a score of 0-2.
  • Normal baseline Echocardiography with left ventricular ejection fraction ≥ 50%.
  • Normal renal and liver function tests.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • Women with HER-2 positive of breast cancer.
  • Formerly treated with Doxorubicin.
  • Patients with a known hypersensitivity to any of the used drugs.
  • On other concomitant vitamins or food supplements.
  • Valvular heart disease, coronary artery disease, history of congestive heart failure or cardiomyopathy.
  • Impaired Left ventricular systolic function in which the Left Ventricular Ejection Fraction \< 50%.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Placebo comparator
    Group 1 (Doxorubicin group)

    30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks.

    Drug: Group 1 (Doxorubicin group)

  • Experimental
    Group 2 (Vitamin D group)

    patients with Vitamin D supplementation (1000 iu/day) plus Doxorubicin for 12 weeks

    Drug: Group 2: Vitamin D group

  • Experimental
    Group 3 (melatonin group)

    30 patients with 10 mg of melatonin orally, once daily plus Doxorubicin for 12 weeks.

    Drug: Group 3: melatonin group

Interventions

  • DrugGroup 1 (Doxorubicin group)

    30 patients will receive a traditional chemotherapeutic agent (Doxorubicin group) for 12 weeks.

  • DrugGroup 2: Vitamin D group

    patients with Vitamin D supplementation (1000 iu/day) plus traditional therapy for 12 weeks

  • DrugGroup 3: melatonin group

    patients with 10 mg of melatonin orally, once daily plus traditional therapy for 12 weeks

06

What researchers measure

Primary outcomes

  1. Decreasing incidence and severity of cardiotoxicity

    Assessment of decreasing incidence and severity of cardiotoxicity by echocardiogram and ejection fraction is associated with doxorubicin treatment.

    Time frame: 12 weeks

Secondary outcomes

  1. change in the serum level of the (biological markers).

    Time frame: 12 weeks

07

Study locations

1 site
  • Tanta University
    Tanta, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — All data will be available when needed

Supporting information: Study protocol, Icf

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Not yet recruiting→Completed
changed Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Not yet recruiting→Completed
    + 2 other changes: date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07349459
Lead sponsor
Tanta University
Responsible party
Majed Essa Alharbi (Resident, Tanta University) — Principal investigator
First posted
Jan 16, 2026
Start date
Apr 30, 2026
Primary completion
Aug 30, 2026
Completion
Aug 30, 2026
Last update
Oct 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion